Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-299a-5p inhibitor
- Development stage
- Preclinical
- Lead developer
- McMaster University
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
miR-299a-5p inhibitor is a research-stage locked nucleic acid (LNA) anti-miR oligonucleotide that competitively inhibits the microRNA miR-299a-5p. Developed by researchers at McMaster University, this compound blocks miR-299a-5p from binding to the 3'UTRs of its target mRNAs, thereby restoring the expression of key endogenous antifibrotic proteins, follistatin (FST) and cripto-1 (CR-1), and the survival kinase MAP3K2. In preclinical models of kidney disease, including diabetic kidney disease and chronic kidney disease, treatment with the miR-299a-5p inhibitor has been shown to reduce renal fibrosis, attenuate tubular cell apoptosis, and decrease albuminuria and glomerular hypertrophy.
- Other names
- LNA anti-miR-299a-5pLNA anti-miR-299a-5p oligonucleotideanti-miR-299a-5panti-miR299a-5panti-miR 299a-5pmiR-299a-5p LNA inhibitormiR299a-5p LNA inhibitormiR 299a-5p LNA inhibitormicroRNA-299a-5p inhibitormicroRNA299a-5p inhibitormicroRNA 299a-5p inhibitor
Beyond the preview
Go deeper on miR-299a-5p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-299a-5p inhibitor.